Bevacizumab (Avastin) and RAD001(Everolimus)in the Treatment of Advanced Clear Cell Renal Carcinoma

Inclusion Criteria: * Histologically documented metastatic or unresectable locally recurrent clear cell renal carcinoma. * In patients with mixed histologies, the clear cell component must comprise ≥ 75% of the cancer * Previous nephrectomy is required with the following exceptions: * Primary tumor \< 5cm * Extensive liver ( \> 30% of liver parenchyma)or * Multiple (\> 5) bone metastases, making nephrectomy a clinically contraindicated procedure * Patients may have had a maximum of 1 previous systemic regimen for metastatic disease * Patients may not have received previous bevacizumab. However, patients who have received other agents with anti-angiogenic activity (eg. sorafenib, SU11248, AG-013736, PTK787, thalidomide) as part of first-line treatment are eligible * Patients may not have received previous treatment with m-TOR inhibitors. * ECOG performance status 0 or 1 * Measurable disease * Adequate liver, kidney and bone marrow function * No previous systemic treatment or radiation therapy for at least 2 weeks prior to study entry * Patients must be able to understand the nature of this study and give written informed consent Exclusion Criteria: * Age \< 18 years * Treatment with \> 1 previous systemic regimen for metastatic renal carcinoma * History of acute myocardial infarction within 6 months * Clinically significant cardiovascular disease * History of stroke within 6 months * Patients with active brain metastases * Patients with meningeal metastases * Women who are pregnant or lactating * Patients who have been treated within 5 years for other invasive cancers * Patients with history or evidence by physical examination of CNS disease * Patients with clinical history of hemoptysis or hematemesis * Patients with history of deep vein thrombosis or thromboembolic disease requiring full dose anticoagulation * Patients with major surgical procedures, open biopsies, or significant traumatic injuries within 28 days or anticipated need for major surgical procedure during the course of the study * Patients with peg-tubes or G-tubes * Patients are ineligible if a fine needle aspiration biopsy has been performed within seven days * Patients with proteinuria * Patients with any non-healing wound, ulcer, or long-bone fracture * Patients with any history of a bleeding diathesis or coagulopathy * History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months * Patients who have received any other experimental drug within 28 days of starting treatment * History of any other severe and/or uncontrolled medical disease * History of HIV infection * Chronic treatment with steroids or other immunosuppressive agents * Patients with impaired GI function that compromises the ability to swallow or absorb RAD001 * Patients who are unwilling or unable to comply with the protocol